Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Concurrent Amplification of Ferroptosis and Immune System Activation Via Nanomedicine‐Mediated Radiosensitization for Triple‐Negative Breast Cancer Therapy

Open access

Abstract

Radiation therapy (RT) is one of the core therapies for current cancer management. However, the emergence of radioresistance has become a major cause of radiotherapy failure and disease progression. Therefore, overcoming radioresistance to achieve highly effective treatment for refractory tumors is significant yet challenging. Here, pH‐responsive DSPE‐PEoz modified hollow Bi 2 Se 3‐RSL3/diABZi (DP‐HBN/RA) nanomedicine is designed as a radiation sensitizer for efficient treatment of triple‐negative breast cancer by simultaneously amplifying ferroptosis and immune system activation. DP‐HBN/RA can efficiently concentrate X‐ray radiation energy inside the tumor, thereby promoting precise ionizing radiation exposure in tumor cells to produce large amounts of reactive oxygen species (ROS), leading to lipid peroxidation‐induced ferroptosis. Meanwhile, ferroptotic cell death is intensified through the inactivation of GPX4 by RSL3 released from DP‐HBN/RA to acidic conditions in the tumor microenvironment. Additionally, DP‐HBN/RA enhances RT efficacy to exacerbate unrepairable DNA damage and release DNA fragments that activate the cGAS‐STING signal pathway, evoking a systematic immune response. Ingeniously, the released diABZi reinforces cGAS‐STING activation to boost the immunology antitumor effect. This work links the induction of ferroptosis and the initiation of systematic immune response to achieve highly effective tumor suppression, which opens up new avenues for future treatments of refractory tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/advs.202407833

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic illustration of the therapeutic mechanism of DP‐HBN/RA with concurrent amplification of ferroptosis and immune system activation ability. The Figure was created with BioRender.com.
Figure 1 Schematic illustration of the therapeutic mechanism of DP‐HBN/RA with concurrent amplification of ferroptosis and immune system activation ability. The Figure was created with BioRender.com.CC BY · PubMed Central
Figure 2 A) The synthesis process of DP‐HBN/RA. The Figure was created with BioRender.com. B) TEM image, scale bar = 20 nm. C) HRTEM image, scale bar = 5 nm. D) XRD pattern of HBN. E) EDS spectrum of HBN. F) DLS of DP‐HBN/RA. G) FTIR spectra of DP‐HBN/RA, HBN, DSPE‐PEOZ, RSL3 and diABZi. H–J) Elemental mapping images of HBN, scale bar = 20 nm.
Figure 2 A) The synthesis process of DP‐HBN/RA. The Figure was created with BioRender.com. B) TEM image, scale bar = 20 nm. C) HRTEM image, scale bar = 5 nm. D) XRD pattern of HBN. E) EDS spectrum of HBN. F) DLS of DP‐HBN/RA. G) FTIR spectra of DP‐HBN/RA, HBN, DSPE‐PEOZ, RSL3 and diABZi. H–J) Elemental mapping images of HBN, scale bar = 20 nm.CC BY · PubMed Central
Figure 3 A) Illustration of CT imaging process. The Figure was created with BioRender.com. B,C) In vitro CT images and associated CT value (HU) of DP‐HBN/RA at different concentrations. D,E) In vivo CT images and associated CT value of the 4T1‐bearing mice after intravenous injection of DP‐HBN/RA at timed intervals (tumor, circle). F) Cellular uptake analysis of DP‐HBN/RA in 4T1 cells, scale bar = 50 µm. G) Cytotoxicity of DP‐HBN and DP‐HBN/RA with different concentrations.
Figure 3 A) Illustration of CT imaging process. The Figure was created with BioRender.com. B,C) In vitro CT images and associated CT value (HU) of DP‐HBN/RA at different concentrations. D,E) In vivo CT images and associated CT value of the 4T1‐bearing mice after intravenous injection of DP‐HBN/RA at timed intervals (tumor, circle). F) Cellular uptake analysis of DP‐HBN/RA in 4T1 cells, scale bar = 50 µm. G) Cytotoxicity of DP‐HBN and DP‐HBN/RA with different concentrations.CC BY · PubMed Central
Figure 4 A) Illustration of cell cycle under RT. The Figure was created with BioRender.com. B,C) Cell cycle analysis and percentage in 4T1 cells with different treatments. D) Flow cytometric analysis of 4T1 cells with different treatments. E) Cytotoxicity of DP‐HBN/RA with Fer‐1 (2 µM) under different treatments.(ANOVA; *** p < 0.001 and **** p < 0.0001) F) Commet assay with different treatments, scale bar = 50 µm. G) DNA damage with γ‐H2AX immunofluorescence with different treatments, scale bar = 50 µm. Data are presented as mean ± standard deviation. (ANOVA; *** p < 0.001 and **** p < 0.0001).
Figure 4 A) Illustration of cell cycle under RT. The Figure was created with BioRender.com. B,C) Cell cycle analysis and percentage in 4T1 cells with different treatments. D) Flow cytometric analysis of 4T1 cells with different treatments. E) Cytotoxicity of DP‐HBN/RA with Fer‐1 (2 µM) under different treatments.(ANOVA; *** p < 0.001 and **** p < 0.0001) F) Commet assay with different treatments, scale bar = 50 µm. G) DNA damage with γ‐H2AX immunofluorescence with different treatments, scale bar = 50 µm. Data are presented as mean ± standard deviation. (ANOVA; *** p < 0.001 and **** p < 0.0001).CC BY · PubMed Central
Figure 5 A) Illustration of DP‐HBN/RA enhances RT efficacy by amplifying ferroptosis. The Figure was created with BioRender.com. B) Total ROS accumulation in 4T1 with different treatments, scale bar = 200 µm. C) MDA level in 4T1 cells with different treatments. D) Fe2+ level in 4T1 cells with different treatments. E) GSH level in 4T1 cells with different treatments. F) MitoROS accumulation in 4T1 cells with different treatments, scale bar = 200 µm. G) Western blotting analysis of ACSL4, PTGS2, SLC7A11, and GPX4 expression in 4T1 cells with different treatments. Data are presented as mean ± standard deviation. (ANOVA; ns for no significance, ** p < 0.01, and **** p < 0.0001).
Figure 5 A) Illustration of DP‐HBN/RA enhances RT efficacy by amplifying ferroptosis. The Figure was created with BioRender.com. B) Total ROS accumulation in 4T1 with different treatments, scale bar = 200 µm. C) MDA level in 4T1 cells with different treatments. D) Fe2+ level in 4T1 cells with different treatments. E) GSH level in 4T1 cells with different treatments. F) MitoROS accumulation in 4T1 cells with different treatments, scale bar = 200 µm. G) Western blotting analysis of ACSL4, PTGS2, SLC7A11, and GPX4 expression in 4T1 cells with different treatments. Data are presented as mean ± standard deviation. (ANOVA; ns for no significance, ** p < 0.01, and **** p < 0.0001).CC BY · PubMed Central
Figure 6 A) Western blotting analysis of pSTING, STING, pTBK1, TBK1, pIRF3, IRF3, and cGAS expression in 4T1 cells with different treatments. B) Expression of CXCL10 C), INF‐β), and D) IL‐6 B in 4T1 supernatant with different treatments. E) Illustration of DP‐HBN/RA amplify cGAS‐STING pathway in tumor cells. The Figure was created with BioRender.com. Data are presented as mean ± standard deviation. (ANOVA; ns for no significance, ** p < 0.01, *** p < 0.001, and **** p < 0.0001).
Figure 6 A) Western blotting analysis of pSTING, STING, pTBK1, TBK1, pIRF3, IRF3, and cGAS expression in 4T1 cells with different treatments. B) Expression of CXCL10 C), INF‐β), and D) IL‐6 B in 4T1 supernatant with different treatments. E) Illustration of DP‐HBN/RA amplify cGAS‐STING pathway in tumor cells. The Figure was created with BioRender.com. Data are presented as mean ± standard deviation. (ANOVA; ns for no significance, ** p < 0.01, *** p < 0.001, and **** p < 0.0001).CC BY · PubMed Central
Figure 7 A) Treatment schema of In vivo antitumor experiments. The Figure was created with BioRender.com. B) Weight of 4T1 xenograft tumors with different treatments. C) Volume of 4T1 xenograft tumors with different time points after different treatments. D) Western blotting analysis of STING‐related proteins in 4T1 xenograft tumors. E) Western blotting analysis of ferroptosis‐related proteins in 4T1 xenograft tumors. F) The photo of lung metastasis at 14 d different treatments. G) TUNEL staining images of 4T1 xenograft tumors at 14 d with different treatments, scale bar = 50 µm. H) H&E staining of lung metastasis sections at 14 d with different treatments, scale bar = 200 µm. Data are presented as mean ± standard deviation. (ANOVA; **** p < 0.0001).
Figure 7 A) Treatment schema of In vivo antitumor experiments. The Figure was created with BioRender.com. B) Weight of 4T1 xenograft tumors with different treatments. C) Volume of 4T1 xenograft tumors with different time points after different treatments. D) Western blotting analysis of STING‐related proteins in 4T1 xenograft tumors. E) Western blotting analysis of ferroptosis‐related proteins in 4T1 xenograft tumors. F) The photo of lung metastasis at 14 d different treatments. G) TUNEL staining images of 4T1 xenograft tumors at 14 d with different treatments, scale bar = 50 µm. H) H&E staining of lung metastasis sections at 14 d with different treatments, scale bar = 200 µm. Data are presented as mean ± standard deviation. (ANOVA; **** p < 0.0001).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Research works printed but not linked: 3

  1. Rothkamm K., 2001, Cancer Res., 61, 3886
  2. Chen X., 2024, AutophagyAutophagy, 1
  3. Ursini F., 2020, Biol. Med., 152, 175

Cited by

See all 31

Metadata

Authors
Aishajiang, R., Liu, Z., Liang, Y., Du, P., Wei, Y., Zhuo, X., Liu, S., Lei, P., Wang, T., & Yu, D.
Affiliations
  • Jilin University (CN)
  • University of Science and Technology of China (CN)
  • Chinese Academy of Sciences (CN)
Corresponding author
  • Lei, Pengpeng
  • Wang, Tiejun
  • Yu, Duo
Venue
Advanced Science
Publisher
Wiley
Published
2024-12-25
Volume
12
Issue
7
Pages
e2407833-e2407833
ISSN
2198-3844 (ISSN-L)
OpenAlex
W4405777268
Cited by
31
References
43
Citations by year
2026: 17 · 2025: 14
FWCI
3.39
Type
journal article
Language
en
Open access
Locations
  • Advanced Science (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (52371254)
  • Jilin Provincial Health and Family Planning Commission (2022LC115)
  • Jilin Province Development and Reform Commission (YDZJ202402068CXJD)
  • Jilin Provincial Scientific and Technological Development Program (419161923009)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
  • Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
Keywords
ferroptosis, triple-negative breast cancer, radiosensitization, radioresistance (biology), Bi2Se3, RSL3, diABZI, GPX4 inhibition, cGAS-STING pathway, systemic immune activation, reactive oxygen species, lipid peroxidation, DNA damage, tumor microenvironment
MeSH terms
Ferroptosis, Animals, Female, Humans, Radiation-Sensitizing Agents, Reactive Oxygen Species, Cell Line, Tumor, Nanomedicine, Mice, Tumor Microenvironment, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Concurrent Amplification of Ferroptosis and Immune System Activation Via Nanomedicine‐Mediated Radiosensitization for Triple‐Negative Breast Cancer Therapy. https://app.cochat.ai/papers/10.1002/advs.202407833
The paper
Aishajiang, R., Liu, Z., Liang, Y., Du, P., Wei, Y., Zhuo, X., Liu, S., Lei, P., Wang, T., & Yu, D. (2025). Concurrent Amplification of Ferroptosis and Immune System Activation Via Nanomedicine‐Mediated Radiosensitization for Triple‐Negative Breast Cancer Therapy. Advanced Science. https://doi.org/10.1002/advs.202407833

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.